AdaptHealth Lowers FY2025 Sales Guidance From $3.22B-$3.36B To $3.18B-$3.32B Vs $3.27B Est; Sees Adjusted EBITDA Of $665M To $705M (Prior $670M To $710M)
Benzinga Newsdesk 1 year ago
NewsGuidance
Financial OutlookThe Company is updating previous financial guidance for fiscal year 2025 to account for the disposition of certain incontinence assets, as follows:Net revenue of $3.18 billion to $3.32 billion, from
Financial Outlook
The Company is updating previous financial guidance for fiscal year 2025 to account for the disposition of certain incontinence assets, as follows:
- Net revenue of $3.18 billion to $3.32 billion, from $3.22 billion to $3.36 billion
- Adjusted EBITDA of $665 million to $705 million, from $670 million to $710 million
- Free cash flow of $180 million to $220 million, unchanged